FWIW, Oppenheimer analyst Bret Holley said $ARIA will price CML drug ponatinib aggressively - near Tasigna/Sprycel
It would be good to hear about the Rida NDA sooner than later. I also think they might to consider raising some capital here ( but maybe they're holding out to partner ex-US rights to Ponatinib?)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.